Latest news

Thumbnail image for Closing soon - ENTER NOW

Closing soon - ENTER NOW

The prestigious PharmaTimes Marketer of the Year competition closes for entries on 1 September. It only takes a few seconds to fill out the online entry form and then you don’t need to do anything else until the day of the competition. This year is extra special as the competition is celebrating its 25th anniversary - and we don't want you to miss out.

17th August 2018

Thumbnail image for Novo buys UK group Ziylo

Novo buys UK group Ziylo

Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out based at Unit DX science incubator in Bristol, UK.

17th August 2018

Thumbnail image for Enter now for a place in history

Enter now for a place in history

It's a double first for the Communications Team of the Year competition, as individuals within agencies and pharma companies battle it out for the 'Aspiring Communications Manager of the Year' title.

17th August 2018

Thumbnail image for Teva, Regeneron’s fasinumab hits osteoarthritis goals

Teva, Regeneron’s fasinumab hits osteoarthritis goals

Teva and Regeneron Pharmaceuticals have unveiled positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.

17th August 2018

Thumbnail image for Lenvima wins green light in liver cancer

Lenvima wins green light in liver cancer

Eisai and MSD’s Lenvima (lenvatinib) has been approved in the US for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

17th August 2018

Thumbnail image for Ortho resubmits Duobrii in the US

Ortho resubmits Duobrii in the US

Bausch Health group Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US

16th August 2018

Thumbnail image for Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo

Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo

The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL).

15th August 2018

Previous  --   9 10 11 12 13 14 15 16 17 18   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download